An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac)

Coronavirus Infections Clinical Trial

Official title:
An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac), Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products", on Volunteers at the Age of 18-60 Years (Clinical Trials, Phase III)

Status Recruiting

Clinical Trial Summary

An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac), Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products", on Volunteers at the Age of 18-60 Years

Clinical Trial Description

The study group is planned to screen a maximum of 32,000 volunteers inclusive, of which it is planned to include 3,500 men and women aged 18 to 60 years who meet the criteria for inclusion in the study and do not have non-inclusion criteria. The study group consisted of 3,500 volunteers who received the CoviVac vaccine Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly at a dose of 0.5 ml and revaccinated at 6 months with one dose of the KoviVac vaccine (0.5 ml). Cohorts: 1. The data of the first 1000 volunteers of subgroup 1 will be used to assess the efficacy + safety + immunogenicity of the vaccine under study. 2. The data of the next 1100 volunteers of subgroup 1 will be used to analyze the efficacy + safety of the vaccine under study. Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml. The data of 1400 volunteers vaccinated three times with an interval of 21 days will be used to assess the effectiveness + safety + immunogenicity of the vaccine under study Control group - official data on the number of Covid-19 cases during the study period among 3,500 unvaccinated individuals. The data of the control group volunteers will be used to evaluate the effectiveness of the vaccine under study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05407142
Study type	Interventional
Source	Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Contact	Aydar Ishmukhametov, M.D.,Prof.,Assoc.Mem.of RAS
Phone	+7(495)841-9002
Email	sue_polio@chumakovs.su
Status	Recruiting
Phase	Phase 3
Start date	July 7, 2021
Completion date	December 29, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04553575` - CoViD-19 Patient in Reims University Hospital in March to April 2020
Active, not recruiting	`NCT05033847` - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above	Phase 2
Active, not recruiting	`NCT05548439` - Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a	Phase 1
Completed	`NCT05046548` - This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19	Phase 1/Phase 2
Active, not recruiting	`NCT05726084` - Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older	Phase 2/Phase 3
Recruiting	`NCT05069129` - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above	Phase 1/Phase 2
Enrolling by invitation	`NCT05054075` - Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19	Phase 2
Recruiting	`NCT05599516` - Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial	Phase 3
Completed	`NCT05047900` - The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community	N/A
Completed	`NCT04420286` - Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France
Completed	`NCT04424355` - Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.
Completed	`NCT05083039` - Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Terminated	`NCT04409873` - Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)	Phase 2
Enrolling by invitation	`NCT04327349` - Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial	N/A
Completed	`NCT04321278` - Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)	Phase 3
Recruiting	`NCT04327570` - In-depth Immunological Investigation of COVID-19.
Completed	`NCT04326309` - Audio Data Collection for Identification and Classification of Coughing
Recruiting	`NCT04322344` - Escin in Patients With Covid-19 Infection	Phase 2/Phase 3
Completed	`NCT04323592` - Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
Completed	`NCT04328129` - Household Transmission Investigation Study for COVID-19 in Tropical Regions	N/A